The health curve has shifted - are you ready?

April 2026

International Private Medical Insurance (IPMI) is entering a new phase. The familiar picture of costs dominated by hospital-based cancer care is giving way to a more complex mix shaped by out-patient pharmacy spend, lifestyle-linked metabolic conditions, and persistent regional divergence in medical trend. Bupa Global’s 2025 Healthcare Insights identify this as the “New Claims Equation,” and it carries important implications for how global employers design benefits, manage risk, and support workforce wellbeing in the years ahead. 

The New Claims Equation: Beyond a single cost driver

For decades, cancer defined the cost curve for IPMI (International Private Medical Insurance). Bupa Global’s latest claims signals show a different balance emerging. Cancer remains a high-cost category, but frequency is rising while severity appears to be easing in some markets, likely reflecting earlier detection and more consistent treatment pathways. Meanwhile, out-patient drug costs and endocrine/metabolic conditions have become much more prominent contributors to overall claims.

This is not a definitive “new normal,” but the direction is clear enough to plan for. The report points to sustained increases in pharmacy spend, especially for diabetes and related metabolic therapies, alongside a visible rise in claims for obesity, cholesterol, and thyroid disorders. GLP‑1 medicines are a notable factor in the wider market. Bupa Global covers these for clinically appropriate type 2 diabetes but not for obesity or weight management, reflecting the need to balance access with sustainability.

Treating medical trend as a single global rate is increasingly impractical. Bupa Global observes early signs of stabilisation in Europe and parts of the Middle East, persistently higher trend in Hong Kong and wider Asia, and a mixed picture across Africa that is amplified by supply chain and currency dynamics. The forward look into 2026 suggests some easing from 2025’s levels, yet the overall trend remains elevated. For multinational employers, that means pricing, plan design, and provider strategies must be tailored to local drivers rather than copied across regions.

Segment differences matter, too. Corporate plans typically see higher out-patient utilisation and mental health support, which are frequent but lower-cost claims. Individual plans skew toward fewer but more severe claims, especially oncology and circulatory care, while SMEs sit between the two with a blend of regular out-patient use and occasional high-cost episodes. Aligning plan features to your population and contracting approach can prevent one segment’s risk profile from distorting the portfolio.

Since 2021, out-patient drug claims have accelerated significantly, with the steepest increases linked to diabetes and other metabolic therapies. Oncology and specialty drugs remain large contributors as well. Regionally, growth in out-patient pharmacy spend has been especially sharp in the Middle East and Europe, with Asia not far behind.

Even where policy coverage for certain drug classes is restricted, broader adoption in health systems raises expectations and demand, exerting indirect pressure on IPMI programs through higher utilisation and shifting care pathways.

For employers, this underscores the value of pharmacy management strategies that go beyond exclusions. Clinically led prior authorisation, step therapy where appropriate, structured use of generics and biosimilars, and centre-of-excellence or in‑network dispensing arrangements can help contain costs while preserving quality and access.

Embedding data-driven medication reviews and aligning virtual care triage with pharmacy benefit design can further dampen avoidable spend. 

Bupa Global’s data shows a marked rise in claims related to diabetes, obesity, thyroid, and cholesterol disorders, with both claim volumes and per-member costs climbing since 2021. This aligns with the global epidemiology of diabetes and cardiovascular disease and signals that metabolic health has moved squarely into the core of employer health risk. Combined with ageing populations, this creates a long tail of ongoing management that influences utilisation across multiple benefit lines, from diagnostics and pharmacy to cardiac and renal care.

Employers can respond by integrating prevention and early detection into plan design and workforce programs. That includes funded or strongly encouraged annual check‑ups, targeted screening for metabolic risks, nutrition and physical-activity interventions, weight management support focused on sustainable behaviour change, and Musculoskeletal (MSK)‑friendly workplace ergonomics that reduce downstream circulatory and metabolic risk.

Where culturally appropriate, incentivising participation through premium differentials or wellness credits can improve uptake without compromising equity. 

Even as claims show signs of stabilisation in some geographies, cancer remains one of the highest-cost categories and will stay central to IPMI for years to come. Earlier-stage detection, clearer clinical pathways, and improved treatments can reduce severity, yet innovation also brings new cost pressures. Breakthrough therapies such as CAR‑T and selected gene therapies can exceed seven figures per patient, raising questions about sustainable funding and the role of pathway management, centre selection, and second opinions.

A pragmatic employer response focuses on three levers:

1. Access to robust second‑opinion services and oncology nurse navigators to ensure the right care, first time
2. Defined pathways and contracted centres of excellence that combine outcomes with predictable pricing
3. Benefits that support survivorship, including mental health, return‑to‑work planning, and monitoring for late effects. 

Beyond oncology and metabolic health, five condition clusters are shaping IPMI’s future cost base:

• Cancer
• Musculoskeletal (MSK)
• Nervous system
• Circulatory
• Respiratory

Together they reflect a world where people live longer with ongoing conditions, and where claims are driven less by one-off hospitalisations and more by continuous management. Post‑pandemic working patterns add to MSK and mental health utilisation, while pollution and volatile infection seasons sustain respiratory demand. The implication for employers is the need to pivot from “coverage-first” to “outcomes-first” strategies that prioritise prevention, navigation, and adherence. 

Treat medical trend as local rather than global. Regional differences in inflation, utilisation, and care pathways mean benefits, pricing expectations, and prevention strategies should be tailored to each geography.

Introduce or enhance screening for diabetes, cholesterol, and other metabolic risks. Pair this with wellbeing programs focused on nutrition, physical activity, weight management, and MSK-friendly workplace practices.

Ensure employees have access to second medical opinions and clear guidance when navigating complex treatments. Benefits that encourage earlier detection, such as screenings and check-ups, help reduce severity and improve outcomes.

Virtual care can serve as an accessible first step for everyday health issues, counselling, or triage, helping employees receive timely care and reducing unnecessary in-person utilisation.

Promote annual health checks and preventive screenings, and ensure employees understand how and when to use their benefits. Clear communication can improve engagement and reduce avoidable high-cost claims.

Bupa Global is the international health insurance division of Bupa, founded in 1947, supporting customers around the world and giving members access to a global healthcare network. It focuses on the all‑round health of its members, combining extensive IPMI coverage with preventive services, virtual care, and clinical case management.

Through MembersWorld, employees can manage their plan and claims online, while Global Virtual Care provides 24/7 access to international doctors. Bupa LifeWorks adds multilingual wellbeing support, and second medical opinion services help members make informed treatment decisions.

As part of its sustainability and innovation agenda, Bupa is investing in digital health solutions and programmes that reduce the environmental footprint of care while enhancing access and outcomes. For multinational employers, this pairing of clinical depth and digital convenience helps create a connected care experience that meets employees where they are—geographically and in their care journey.